The Pore-Lipid Interface: Role of Amino-Acid Determinants of Lipophilic Access by Ivabradine to the hERG1 Pore Domain

Abnormal cardiac electrical activity is a common side effect caused by unintended block of the promiscuous drug target human ether-à-go-go-related gene (hERG1), the pore-forming domain of the delayed rectifier K+ channel in the heart. hERG1 block leads to a prolongation of the QT interval, a phase of the cardiac cycle that underlies myocyte repolarization detectable on the electrocardiogram. Even newly released drugs such as heart-rate lowering agent ivabradine block the rapid delayed rectifier current IKr, prolong action potential duration, and induce potentially lethal arrhythmia known as torsades de pointes. In this study, we describe a critical drug-binding pocket located at the lateral pore surface facing the cellular membrane. Mutations of the conserved M651 residue alter ivabradine-induced block but not by the common hERG1 blocker dofetilide. As revealed by molecular dynamics simulations, binding of ivabradine to a lipophilic pore access site is coupled to a state-dependent reorientation of aromatic residues F557 and F656 in the S5 and S6 helices. We show that the M651 mutation impedes state-dependent dynamics of F557 and F656 aromatic cassettes at the protein-lipid interface, which has a potential to disrupt drug-induced block of the channel. This fundamentally new mechanism coupling the channel dynamics and small-molecule access from the membrane into the hERG1 intracavitary site provides a simple rationale for the well established state-dependence of drug blockade. SIGNIFICANCE STATEMENT The drug interference with the function of the cardiac hERG channels represents one of the major sources of drug-induced heart disturbances. We found a novel and a critical drug-binding pocket adjacent to a lipid-facing surface of the hERG1 channel, which furthers our molecular understanding of drug-induced QT syndrome.

[1]  Benoît Roux,et al.  Control of ion selectivity in LeuT: two Na+ binding sites with two different mechanisms. , 2008, Journal of molecular biology.

[2]  Roderick MacKinnon,et al.  Structure of the voltage-gated K+ channel Eag1 reveals an alternative voltage sensing mechanism , 2016, Science.

[3]  W. N. Zagotta,et al.  Localization of regions affecting an allosteric transition in cyclic nucleotide-activated channels , 1995, Neuron.

[4]  M. Sanguinetti,et al.  Cooperative subunit interactions mediate fast C‐type inactivation of hERG1 K+ channels , 2014, The Journal of physiology.

[5]  Roderick MacKinnon,et al.  Cryo-EM Structure of the Open Human Ether-à-go-go-Related K+ Channel hERG , 2017, Cell.

[6]  Torsten Schwede,et al.  The SWISS-MODEL Repository of annotated three-dimensional protein structure homology models , 2004, Nucleic Acids Res..

[7]  B. Roux,et al.  Control of ion selectivity in potassium channels by electrostatic and dynamic properties of carbonyl ligands , 2004, Nature.

[8]  Henggui Zhang,et al.  High-throughput screening of drug-binding dynamics to HERG improves early drug safety assessment. , 2013, American journal of physiology. Heart and circulatory physiology.

[9]  Jianpeng Ma,et al.  CHARMM: The biomolecular simulation program , 2009, J. Comput. Chem..

[10]  J. Mason,et al.  Genetically defined therapy of inherited long-QT syndrome. Correction of abnormal repolarization by potassium. , 1996, Circulation.

[11]  J. Balser,et al.  Probing the Interaction Between Inactivation Gating and d-Sotalol Block of HERG , 2000, Circulation research.

[12]  Matthew P. Repasky,et al.  Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. , 2006, Journal of medicinal chemistry.

[13]  J. P. Grossman,et al.  Anton 2: Raising the Bar for Performance and Programmability in a Special-Purpose Molecular Dynamics Supercomputer , 2014, SC14: International Conference for High Performance Computing, Networking, Storage and Analysis.

[14]  M. Sanguinetti,et al.  Long-QT Syndrome-Associated Missense Mutations in the Pore Helix of the HERG Potassium Channel , 2001, Circulation.

[15]  Jens Meiler,et al.  Protocols for Molecular Modeling with Rosetta3 and RosettaScripts , 2016, Biochemistry.

[16]  A. Bauer-Brandl,et al.  Towards an understanding of the molecular mechanism of solvation of drug molecules: a thermodynamic approach by crystal lattice energy, sublimation, and solubility exemplified by paracetamol, acetanilide, and phenacetin. , 2006, Journal of pharmaceutical sciences.

[17]  J. Hancox,et al.  hERG potassium channel inhibition by ivabradine may contribute to QT prolongation and risk of torsades de pointes , 2015, Therapeutic advances in drug safety.

[18]  Jules C. Hancox,et al.  hERG Potassium Channel Blockade by the HCN Channel Inhibitor Bradycardic Agent Ivabradine , 2015, Journal of the American Heart Association.

[19]  S. Heinemann,et al.  Molecular determinants for activation and inactivation of HERG, a human inward rectifier potassium channel. , 1996, The Journal of physiology.

[20]  Michael J. Ackerman,et al.  Physiological Properties of hERG 1a/1b Heteromeric Currents and a hERG 1b-Specific Mutation Associated With Long-QT Syndrome , 2008, Circulation research.

[21]  H. Duff,et al.  Determinants of Isoform-Specific Gating Kinetics of hERG1 Channel: Combined Experimental and Simulation Study , 2018, Front. Physiol..

[22]  Kevin R. DeMarco,et al.  Digging into Lipid Membrane Permeation for Cardiac Ion Channel Blocker d-Sotalol with All-Atom Simulations , 2018, Front. Pharmacol..

[23]  M. Sanguinetti,et al.  SYMPOSIUM REVIEW: Revealing the structural basis of action of hERG potassium channel activators and blockers , 2010, The Journal of physiology.

[24]  A. Zamyatnin,et al.  Protein volume in solution. , 1972, Progress in biophysics and molecular biology.

[25]  A. Bauer-Brandl,et al.  Thermodynamics of Solutions I: Benzoic Acid and Acetylsalicylic Acid as Models for Drug Substances and the Prediction of Solubility , 2003, Pharmaceutical Research.

[26]  Sergei Yu Noskov,et al.  Performance of Machine Learning Algorithms for Qualitative and Quantitative Prediction Drug Blockade of hERG1 channel. , 2017, Computational toxicology.

[27]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[28]  M. Sanguinetti,et al.  A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel , 1995, Cell.

[29]  Henry J. Duff,et al.  Exaggerated block of hERG (KCNH2) and prolongation of action potential duration by erythromycin at temperatures between 37°C and 42°C , 2005 .

[30]  Stefan A. Mann,et al.  Kinetics of Drug Interaction with the Kv11.1 Potassium Channel , 2014, Molecular Pharmacology.

[31]  M. Sanguinetti,et al.  Fast inactivation causes rectification of the IKr channel , 1996, The Journal of general physiology.

[32]  Brian K Shoichet,et al.  Structure-based drug screening for G-protein-coupled receptors. , 2012, Trends in pharmacological sciences.

[33]  J. Nerbonne,et al.  Molecular physiology of cardiac repolarization. , 2005, Physiological reviews.

[34]  F. Sachse,et al.  Structural basis of action for a human ether-a-go-go-related gene 1 potassium channel activator , 2007, Proceedings of the National Academy of Sciences.

[35]  R Lazzara,et al.  Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. , 1996, Circulation.

[36]  G. Perlovich,et al.  Solubility, lipophilicity and membrane permeability of some fluoroquinolone antimicrobials. , 2016, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[37]  R. Dror,et al.  Gaussian split Ewald: A fast Ewald mesh method for molecular simulation. , 2005, The Journal of chemical physics.

[38]  Henggui Zhang,et al.  hERG Inhibitors with Similar Potency But Different Binding Kinetics Do Not Pose the Same Proarrhythmic Risk: Implications for Drug Safety Assessment , 2014, Journal of cardiovascular electrophysiology.

[39]  Y. Rudy,et al.  Mutation Associated with Long-qt Syndrome Physiological Properties of Herg 1a/1b Heteromeric Currents and a Herg 1b-specific Physiological Properties of Herg 1a/1b Heteromeric Currents and a Herg 1b-specific Mutation Associated with Long-qt Syndrome Ultrarapid Communication Materials and Methods Cel , 2008 .

[40]  Henry J Duff,et al.  Exaggerated block of hERG (KCNH2) and prolongation of action potential duration by erythromycin at temperatures between 37 degrees C and 42 degrees C. , 2005, Heart rhythm.

[41]  Stephen H. White,et al.  Experimentally determined hydrophobicity scale for proteins at membrane interfaces , 1996, Nature Structural Biology.

[42]  Sergei Yu Noskov,et al.  Evaluations of the Absolute and Relative Free Energies for Antidepressant Binding to the Amino Acid Membrane Transporter LeuT with Free Energy Simulations. , 2010, Journal of chemical theory and computation.

[43]  M. Sanguinetti,et al.  Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[44]  H. Duff,et al.  Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites. , 2000, Molecular pharmacology.

[45]  G. Robertson,et al.  Transfer of rapid inactivation and sensitivity to the class III antiarrhythmic drug E‐4031 from HERG to M‐eag channels , 1998, The Journal of physiology.

[46]  M. Sanguinetti,et al.  Mutations in the hminK gene cause long QT syndrome and suppress lKs function , 1997, Nature Genetics.

[47]  Laxmikant V. Kalé,et al.  Scalable molecular dynamics with NAMD , 2005, J. Comput. Chem..

[48]  T J Campbell,et al.  HERG K+ channels: friend and foe. , 2001, Trends in pharmacological sciences.

[49]  M. Sanguinetti HERG1 channel agonists and cardiac arrhythmia. , 2014, Current opinion in pharmacology.

[50]  G. Robertson,et al.  HERG, a human inward rectifier in the voltage-gated potassium channel family. , 1995, Science.

[51]  Harry J Witchel,et al.  Drug-induced hERG block and long QT syndrome. , 2011, Cardiovascular therapeutics.

[52]  A. Bauer-Brandl,et al.  Thermodynamics of sublimation, crystal lattice energies, and crystal structures of racemates and enantiomers: (+)- and (+/-)-ibuprofen. , 2004, Journal of pharmaceutical sciences.

[53]  Serdar Durdagi,et al.  Role of the pH in state-dependent blockade of hERG currents , 2016, Scientific Reports.

[54]  M. Klein,et al.  Constant pressure molecular dynamics algorithms , 1994 .

[55]  Gavin Walker,et al.  Creating Cocrystals: A Review of Pharmaceutical Cocrystal Preparation Routes and Applications , 2018, Crystal Growth & Design.

[56]  Alexander D. MacKerell,et al.  Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone φ, ψ and side-chain χ(1) and χ(2) dihedral angles. , 2012, Journal of chemical theory and computation.

[57]  G. Robertson,et al.  hERG subunit composition determines differential drug sensitivity , 2011, British journal of pharmacology.

[58]  T. Allen,et al.  Towards a Structural View of Drug Binding to hERG K+ Channels. , 2017, Trends in pharmacological sciences.

[59]  B. L. de Groot,et al.  CHARMM36m: an improved force field for folded and intrinsically disordered proteins , 2016, Nature Methods.

[60]  Alexander D. MacKerell,et al.  Update of the CHARMM all-atom additive force field for lipids: validation on six lipid types. , 2010, The journal of physical chemistry. B.

[61]  C. Chothia The nature of the accessible and buried surfaces in proteins. , 1976, Journal of molecular biology.

[62]  J. Nerbonne,et al.  Potassium currents in the heart: functional roles in repolarization, arrhythmia and therapeutics , 2017, The Journal of physiology.

[63]  H. Duff,et al.  High- and low-affinity sites for [3H]dofetilide binding to guinea pig myocytes. , 1995, Circulation research.

[64]  L. Eckardt,et al.  Antiarrhythmic properties of ivabradine in an experimental model of Short‐QT‐ Syndrome , 2017, Clinical and experimental pharmacology & physiology.

[65]  A. Brown,et al.  Molecular determinants of dofetilide block of HERG K+ channels. , 1998, Circulation research.

[66]  Viktor Hornak,et al.  Using Membrane Partitioning Simulations To Predict Permeability of Forty-Nine Drug-Like Molecules , 2018, J. Chem. Inf. Model..

[67]  J. Thompson,et al.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.

[68]  Stefan A. Mann,et al.  hERG K(+) channels: structure, function, and clinical significance. , 2012, Physiological reviews.

[69]  State dependent dissociation of HERG channel inhibitors , 2007 .

[70]  H. Duff,et al.  Ivabradine prolongs phase 3 of cardiac repolarization and blocks the hERG1 (KCNH2) current over a concentration-range overlapping with that required to block HCN4. , 2015, Journal of molecular and cellular cardiology.

[71]  M. Sanguinetti,et al.  The Link between Inactivation and High-Affinity Block of hERG1 Channels , 2015, Molecular Pharmacology.

[72]  Taehoon Kim,et al.  CHARMM‐GUI: A web‐based graphical user interface for CHARMM , 2008, J. Comput. Chem..

[73]  A. Menini,et al.  Cyclic Nucleotide-Activated Channels , 1994 .

[74]  M. Trudeau,et al.  A recombinant N-terminal domain fully restores deactivation gating in N-truncated and long QT syndrome mutant hERG potassium channels , 2009, Proceedings of the National Academy of Sciences.

[75]  Jun Chen,et al.  A structural basis for drug-induced long QT syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[76]  Jennifer L. Knight,et al.  OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins. , 2016, Journal of chemical theory and computation.

[77]  Karel Berka,et al.  MOLEonline 2.0: interactive web-based analysis of biomacromolecular channels , 2012, Nucleic Acids Res..

[78]  A. Stary-Weinzinger,et al.  New potential binding determinant for hERG channel inhibitors , 2016, Scientific Reports.

[79]  Alexander D. MacKerell,et al.  All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.

[80]  Thomas A. Halgren,et al.  Identifying and Characterizing Binding Sites and Assessing Druggability , 2009, J. Chem. Inf. Model..